GlassScriptPhysician profile
Chad A Hamilton
NPI 1699733808
$242,115.42
in general payments reported to CMS, 2019-2025
29 companies · $63K in 2025
The $63K reported for 2025 was more than what 98% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $12K · 2021: $25K · 2022: $18K · 2023: $26K · 2024: $56K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Consulting Fee: $46K · Travel and Lodging: $5,091 · Food and Beverage: $3,069 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,683.00 |
| Consulting Fee | $45,630.00 |
| Travel and Lodging | $5,090.81 |
| Food and Beverage | $3,069.09 |
| Education | $220.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $146,356.70 | 2020-2025 | Jemperli, Zejula |
| Tesaro, INC. | $36,674.67 | 2019 | |
| Abbvie INC. | $29,130.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $16,806.83 | 2019-2025 | Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $6,561.92 | 2019-2025 | Keytruda, Lynparza |
| Pfizer INC. | $2,160.00 | 2025 | |
| Genmab U.S., INC. | $2,032.36 | 2022-2025 | Epkinly, Tivdak |
| Eisai INC. | $535.51 | 2021-2023 | |
| Intuitive Surgical, INC. | $300.18 | 2019-2024 | |
| Biom'Up Sa | $293.87 | 2019 | |
| Caris Mpi, INC. | $235.67 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $193.87 | 2019 | |
| Biom'Up France Sas | $147.30 | 2021 | |
| Clovis Oncology, INC. | $91.61 | 2019 | |
| Foundation Medicine, INC. | $86.30 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $80.30 | 2024-2025 | Enhertu, Datroway |
| Smith+Nephew, INC. | $78.30 | 2019 | |
| Kyowa Kirin, INC. | $53.51 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $48.38 | 2021-2023 | Precisetumor |
| Immunogen, INC. | $41.76 | 2023 | Elahere |
| Tempus Ai, INC | $29.68 | 2024 | Xt Cdx |
| Bayer Healthcare Pharmaceuticals INC. | $28.78 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $28.16 | 2024 | Exparel |
| Amgen INC. | $26.87 | 2019 | |
| Heron Therapeutics, INC. | $26.78 | 2019 | |
| Davol INC. | $20.91 | 2020 | |
| Becton, Dickinson and Company | $15.40 | 2019 | |
| Stryker Corporation | $15.01 | 2020 | |
| Hologic Sales and Service, LLC | $14.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.